Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Vorinostat in Combination With Radiation Therapy and Infusional Fluorouracil (5-FU) in Patients With Locally Advanced Adenocarcinoma of the Pancreas

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2012 by Massachusetts General Hospital.
Recruitment status was:  Active, not recruiting
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Lawrence S. Blaszkowsky, MD, Massachusetts General Hospital Identifier:
First received: July 27, 2009
Last updated: April 25, 2012
Last verified: April 2012
The durg vorinostat (Zolinza) is a type of drug called an histone deacetylase (HDAC) inhibitor. It inhibits a group of enzymes called histone deacetylases. These enzymes help cancer cells survive. By inhibiting these enzymes, vorinostat helps kill cancer cells. In this research study vorinostat will be given along with radiation therapy and the drug 5-FU. This is the first research study in which vorinostat will be given along with radiation therapy and 5-FU. The purpose of this research study is to find the highest dose of vorinostat that can be given safely along with radiation therapy and 5-FU. The investigators will also begin to get information about whether vorinostat combined with radiation and 5-FU may help to treat pancreatic cancer.

Condition Intervention Phase
Pancreatic Cancer
Adenocarcinoma of the Pancreas
Radiation: Radiation therapy
Drug: 5-FU
Drug: Vorinostat
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1/2 Study of Vorinostat in Combination With Radiation Therapy and Infusional 5-FU in Patients With Locally Advanced Adenocarcinoma of the Pancreas

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Determine the maximally tolerated dose (MTD) and tolerability of vorinostat in combination with infusional 5-FU and radiation therapy. [ Time Frame: 2 years ]
  • Progression free survival at 7 months from registration [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Determine progression free survival [ Time Frame: 2 years ]
  • Determine toxicity profile [ Time Frame: 2 years ]
  • Median survival, response rate and resectability rate [ Time Frame: 2 years ]

Estimated Enrollment: 50
Study Start Date: August 2009
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Radiation: Radiation therapy
    Once per day, 5 days a week for 6 weeks
    Drug: 5-FU
    Intravenously over 24 hours, 7 days per week during each week of radiation therapy
    Drug: Vorinostat
    Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
    Other Name: Zolinza
Detailed Description:
  • Since we are looking for the highest dose of vorinostat that can be administered safely without severe or unmanageable side effects, not everyone who participates will receive the same dose. The dose will depend upon the number of participants enrolled on the study and how well they have tolerated their doses.
  • 5-FU will be given intravenously over 24 hours 7 days per week during each week of radiation therapy. In order for participants to be able to receive the 5-FU as an outpatient, they will need to have central line catheter placed.
  • Radiation therapy will be given once per day, 5 days per week, for 6 weeks.
  • Vorinostat is taken orally.
  • Participants will be seen once per week during the 6 weeks that they are receiving 5-FU, radiation therapy and vorinostat.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically proven adenocarcinoma of the pancreas
  • Evaluable disease
  • Must have received 3-4 months of gemcitabine-based chemotherapy and have had stable disease by RECIST criteria. Regimens include:

    • gemcitabine alone
    • gemcitabine and erlotinib
    • gemcitabine and oxaliplatin
    • gemcitabine and cisplatin
    • gemcitabine and capecitabine
  • 18 years of age or older
  • Life expectancy of greater than 4 months
  • ECOG Performance Status 0-1
  • Normal organ and marrow function as outlined in the protocol
  • Ability to drink at least 2 liters of fluid daily
  • Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation
  • Patients must be able to swallow capsules

Exclusion Criteria:

  • Chemotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
  • Participants may not be receiving any other study agents
  • Known distant metastases to any organ
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or 5-FU
  • Patients taking warfarin due to potential interactions of both 5-FU and vorinostat. Low molecular weight heparin should be substituted when appropriate
  • Patients who have received upper abdominal radiation therapy which fields would overlap with that determined necessary to treat the primary tumor.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant or breastfeeding women
  • Individuals with history of a different malignancy are ineligible unless they are deemed by the investigator to be at low risk of recurrence of that malignancy. Patients may not have a concurrent second malignancy.
  • Active HIV or hepatitis
  • Prior exposure to HDAC inhibitor (except valproic acid, provided there is a 30 day washout period)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00948688

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Merck Sharp & Dohme Corp.
Principal Investigator: Lawrence Blaszkowsky, MD Massachusetts General Hospital
  More Information

Responsible Party: Lawrence S. Blaszkowsky, MD, Assistant Physician, Massachusetts General Hospital Identifier: NCT00948688     History of Changes
Other Study ID Numbers: 09-114
Study First Received: July 27, 2009
Last Updated: April 25, 2012

Keywords provided by Massachusetts General Hospital:

Additional relevant MeSH terms:
Pancreatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents processed this record on April 24, 2017